Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Non-cash Items (2023 - 2025)

Historic Non-cash Items for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $15.5 million.

  • Compass Therapeutics' Non-cash Items rose 2916.67% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 2916.67%. This contributed to the annual value of $579000.0 for FY2024, which is 516363.64% up from last year.
  • Latest data reveals that Compass Therapeutics reported Non-cash Items of $15.5 million as of Q3 2025, which was up 2916.67% from $19.5 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Non-cash Items peaked at $21.5 million during Q1 2025, and registered a low of $11000.0 during Q4 2023.
  • For the 3-year period, Compass Therapeutics' Non-cash Items averaged around $11.5 million, with its median value being $11.7 million (2024).
  • Examining YoY changes over the last 5 years, Compass Therapeutics' Non-cash Items showed a top increase of 516363.64% in 2024 and a maximum decrease of 88.5% in 2024.
  • Over the past 3 years, Compass Therapeutics' Non-cash Items (Quarter) stood at $11000.0 in 2023, then surged by 5163.64% to $579000.0 in 2024, then surged by 2577.03% to $15.5 million in 2025.
  • Its Non-cash Items was $15.5 million in Q3 2025, compared to $19.5 million in Q2 2025 and $21.5 million in Q1 2025.